Gamma-secretase
Complex in Homo sapiens that 6 drugs act on.
- Drugs that act on it: 6
- Approved: 1
- In phases 1 to 3: 5
- Sponsors: 6
- Genes: 6
Who is on it, and how far along
Every drug ChEMBL records acting on APH1A, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 6
Sponsors
Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.
- Bristol-Myers Squibb117%
- Eli Lilly117%
- Merck KGaA117%
- Myrexis Inc.117%
- Roche117%
- Wyeth is now a wholly owned subsidiary of Pfizer117%
| Nirogacestat | Approved | Merck KGaA | Small molecule | Inhibitor | 14 |
| Semagacestat | Phase 3 | Eli Lilly | Small molecule | Inhibitor | 0 |
| Tarenflurbil | Phase 3 | Myrexis Inc. | Small molecule | ModulatorGamma-secretase modulator | 0 |
| Avagacestat | Phase 2 | Bristol-Myers Squibb | Small molecule | Inhibitor | 0 |
| Begacestat | Phase 2 | Wyeth is now a wholly owned subsidiary of Pfizer | Small molecule | Inhibitor | 0 |
| RG-4733 | Phase 2 | Roche | Small molecule | Inhibitor | 0 |
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2094135, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-22. ChEMBL and Open Targets